Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Equity Average (2016 - 2025)

Ultragenyx Pharmaceutical has reported Equity Average over the past 10 years, most recently at -$35.4 million for Q4 2025.

  • Quarterly Equity Average fell 111.77% to -$35.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$35.4 million through Dec 2025, down 111.77% year-over-year, with the annual reading at $87.5 million for FY2025, 66.98% down from the prior year.
  • Equity Average was -$35.4 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $80.2 million in the prior quarter.
  • Over five years, Equity Average peaked at $1.1 billion in Q1 2021 and troughed at -$35.4 million in Q4 2025.
  • The 5-year median for Equity Average is $293.6 million (2024), against an average of $442.5 million.
  • Year-over-year, Equity Average skyrocketed 384.77% in 2024 and then plummeted 111.77% in 2025.
  • A 5-year view of Equity Average shows it stood at $928.1 million in 2021, then plummeted by 55.78% to $410.4 million in 2022, then crashed by 62.63% to $153.4 million in 2023, then skyrocketed by 96.22% to $300.9 million in 2024, then tumbled by 111.77% to -$35.4 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Equity Average are -$35.4 million (Q4 2025), $80.2 million (Q3 2025), and $147.8 million (Q2 2025).